Sartorius AG
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sartorius AG - overview
Established
1870
Location
Gottingen, -, Germany
Primary Industry
Medical Devices & Equipment
About
Sartorius AG, based in Germany, specializes in providing innovative solutions for the biopharmaceutical and laboratory sectors, enhancing research efficiency through advanced equipment and services. Sartorius AG is a global player in the biopharmaceutical industry, founded in 1870 in Göttingen, Germany. The firm primarily operates in the biopharmaceutical market and does not have reported subsidiaries. Romain Comte serves as the CEO of the company.
In October 2021, Armira, along with the company's management, acquired a 56. 7% majority stake in Sartorius AG, though financial terms weren't disclosed. The company has completed one deal as of 2021. Sartorius specializes in a comprehensive range of products and services tailored for the biopharmaceutical and laboratory sectors.
Their offerings include advanced bioprocessing equipment, lab instrumentation, and consumables designed to enhance scientific research and production efficiency. Key products feature single-use bioreactors, biolayer interferometry systems, and cell culture media, all aimed at meeting the needs of biopharmaceutical manufacturers and research laboratories. Sartorius's solutions address critical challenges in drug development and vaccine production, serving a diverse clientele across North America, Europe, and Asia. In the financial year 2024, Sartorius generated revenue of USD 3,658.
68 mn, with an EBITDA of USD 424. 88 mn. The company's revenue primarily comes from high-tech equipment sales and associated services in the biopharmaceutical and life sciences sectors, often involving direct sales and long-term service agreements. Sartorius AG is focused on expanding its product offerings by designing new solutions aimed at bioprocess automation and advanced data analytics.
The company aims to penetrate new geographical markets, specifically targeting regions in Asia and North America by 2025. The funding from the recent acquisition in October 2021 is expected to support these initiatives, enhancing their capabilities in research and development as well as expanding their market footprint.
Current Investors
Armira Partners
Primary Industry
Medical Devices & Equipment
Sub Industries
Biopharmaceuticals, Medical Equipment Distributors, Medical Supplies, Pharmaceutical Research & Development, Specialty Pharmaceuticals
Website
www.sartorius.com
Verticals
E-commerce, Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Sartorius AG - timeline of key events
Sartorius AG - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 659,317,000 | 733,100,000 | 845,710,000 | 887,269,000 | 891,168,000 | 1,114,752,000 | 1,300,296,000 | 1,404,569,000 | 1,566,033,000 | 1,826,966,000 | 2,335,657,000 | 3,449,222,000 | - | - | - |
| % Revenue Growth (YoY) | - | 11.2% | 15.4% | 4.9% | 0.4% | 25.1% | 16.6% | 8.0% | 11.5% | 16.7% | 27.8% | 47.7% | - | - | - |
| EBITDA (USD) | 103,928,000 | 125,955,000 | 150,032,000 | 164,036,000 | 181,093,000 | 251,199,000 | 296,172,000 | 317,717,000 | 411,988,000 | 468,248,000 | 636,699,000 | 1,134,331,000 | - | - | - |
| Operating Income (USD) | 72,075,000 | 93,148,000 | 109,402,000 | 116,308,000 | 126,188,000 | 192,347,000 | 220,466,000 | 219,357,000 | 298,614,000 | 335,663,000 | 456,106,000 | 903,155,000 | - | - | - |
| Operating Margin | 10.9% | 12.7% | 12.9% | 13.1% | 14.2% | 17.3% | 17.0% | 15.6% | 19.1% | 18.4% | 19.5% | 26.2% | - | - | - |
| % EBITDA Margin | 15.8% | 17.2% | 17.7% | 18.5% | 20.3% | 22.5% | 22.8% | 22.6% | 26.3% | 25.6% | 27.3% | 32.9% | - | - | - |
| NET Income (USD) | 40,684,000 | 52,795,000 | 64,254,000 | 70,639,000 | 68,443,000 | 158,239,000 | 145,002,000 | 159,326,000 | 197,478,000 | 218,743,000 | 321,472,000 | 426,978,000 | - | - | - |
| % Net Margin | 6.2% | 7.2% | 7.6% | 8.0% | 7.7% | 14.2% | 11.2% | 11.3% | 12.6% | 12.0% | 13.8% | 12.4% | - | - | - |
Sartorius AG - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A | Completed | Repairon GmbH | - | ||||||||
| Add-on, Corporate Carve Out | Completed | Visikol, Inc. | - | ||||||||
| Add-on, Corporate Carve Out | Completed | MatTek Life Sciences | - | ||||||||
| Add-on, Trade Sale | Completed | Polyplus-transfection SA | - | ||||||||
| Series A | Completed | Curexsys GmbH | - |
Displaying 1 - 5 of 12
Sartorius AG - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.